NCT01069510已完成2 期
Heart Failure in Congenital Heart Disease: the Role of Myocardial Fibrosis. Treatment Sub-Study: Spironolactone vs. Placebo
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Extracellular Volume Fraction
研究概览
简要总结
The purpose of this study is to see if the study drug called spironolactone reduces fibrous (stiffening) in heart muscle tissue and improves heart function. Subjects from the study titled "Heart Failure in Congenital Heart Disease: the role of myocardial fibrosis" who have evidence of heart dysfunction and/or evidence of fibrosis (stiffening) in the heart muscle will be asked to take part in this study.
详细描述
This study will include randomizing the subject to receive the study drug or placebo. Randomization will occur during visit 1.
Visit 1 will include the following:
- Subjects will answer questions about how well they can breathe.
- An MRI. Dye called gadolinium will be injected into the subject's vein.
- They will go to the Oregon Clinical and Translational Research Institute where 2 tablespoons of blood will be drawn from an intravenous (IV) catheter (tube).
- They will do a 6 minute walk test..
- They will also have an echocardiogram, which is a test that looks at the movement of the subject's heart. A technician will place a cool jelly on their chest and use a small wand to take pictures through the skin.
Subjects' will also have visits 3-6 weeks, 3, 6, 9 months, and 12 months after randomization. Visits 2-5 will include the following:
- They will go to the Oregon Clinical and Translational Research Institute where 1/2 tablespoon of blood will be drawn.
- They will do a 6 minute walk test. During this test, they will walk back and forth in a hallway. The goal is to walk as far as possible for 6 minutes. Subjects will probably get out of breath or become exhausted. If they do, they can slow down, stop, or rest as they need to. Blood pressure will be taken before the walk.
- They will have a health review at 6 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fibrosis index ≥29%, or
- •Evidence of cardiovascular dysfunction including any of the following:
- •Systemic ejection fraction <55%,
- •6-minute walk distance <500 m.
- •Completion of Visit 1 of the study Heart Failure in Congenital Heart Disease: the role of myocardial fibrosis" (eIRB # 3665) including meeting all inclusion for that study (Aged 18-80, Known congenital heart disease).
- •Tetralogy of Fallot, cyanotic congenital heart disease, or a systemic right ventricle.
排除标准
- •Patient currently taking spironolactone or previously taking spironolactone within the last 6 months.
- •Serum potassium ≥5.0 mmol/L at the initial visit, if not taking potassium supplements. Patients will be eligible if a repeat potassium is <5.0 mmol/L after potassium supplements have been discontinued.
- •Moderate/severe systemic atrioventricular valve regurgitation,
- •Likely to undergo cardiac surgery, pacemaker implantation, or possible transplantation within one year (all self-reported),
- •Unwilling to commit to return visits including mandatory blood draws for potassium,
- •Renal insufficiency (estimated creatinine clearance < 30 ml/min/1.73m2),
- •Positive urine pregnancy test.
- •Any contraindication to MRI.
研究组 & 干预措施
Placebo
Placebo Comparator
Patients will receive placebo
干预措施: Placebo (Other)
Spironolactone
Experimental
Spironolactone 25 mg daily
干预措施: Spironolactone 25mg (Drug)
结局指标
主要结局
Extracellular Volume Fraction
时间窗: 12 month
extracellular volume fraction measured by T1 mapping with MRI
次要结局
- 6-minute Walk Distance(12 month)
- Procollagen 3 NT Peptide(12 months)
研究者
Craig Broberg
Associate Professor
Oregon Health and Science University
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Hemodynamic Effects of Spironolactone in Patients With Heart FailureCongestive Heart FailureNCT00860340University of Toledo Health Science Campus18
终止
3 期
Spironolactone in the Treatment of Heart FailureNCT04727073Charite University, Berlin, Germany743
尚未招募
4 期
Heart Transplant Myocardial Fibrosis StudyDiastolic dysfunctionMyocardial fibrosis after heart transplantationCardiovascular - Other cardiovascular diseasesACTRN12606000193572The Alfred Hospital40
已完成
不适用
Validation of New Therapeutic Targets to Prevent Collagen Accumulation During Cardiac Fibrosis: Procollagen C-proteinase EnhancersValvulopathyHeart SurgeryProcollagen C-Proteinase EnhancersNCT04820959Centre Hospitalier Universitaire Dijon66
招募中
3 期
SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fractioHeart failure with preserved or mid-range ejection fractionHFmrEF and HFpEF10019280NL-OMON54576Charité Universitätsmedizin Berlin100